{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:56:27Z","timestamp":1787025387797,"version":"build-2736575974"},"reference-count":30,"publisher":"Scientific Scholar","content-domain":{"domain":["ijmr.org.in"],"crossmark-restriction":true},"short-container-title":["Indian J Med Res"],"abstract":"\n Background & objectives<\/jats:title>\n The role of behavioural therapies for alcohol use disorder (AUD) has been reported in patients with alcohol-related liver disease (ALD); however, that of pharmacological treatments is yet to be established. We conducted a systematic review and meta-analysis to study the use of these pharmacological interventions in ALD for liver-related and patient-important outcomes, including abstinence.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We conducted a systematic search of four major databases. Title and abstract screening, full-text review, risk of bias assessment, and data extraction were performed independently by two reviewers. Random-effects meta-analysis was used to calculate pooled effect estimates with 95 per cent confidence intervals (CI). The certainty of the evidence was assessed using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) tool and categorised as high, moderate, low, or very low.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Altogether, eleven studies (1 RCT and 10 cohort studies) were included in the systematic review and eight studies in the meta-analyses. Meta-analysis of two cohort studies (44813 participants) showed significantly lower odds of all-cause mortality with the use of AUD pharmacotherapy with acceptable statistical heterogeneity [Odds Ratio (OR) 0.86; 95% CI 0.79\u20130.93; I\n 2<\/jats:sup>\n = 0%]. Meta-analysis of one RCT and three cohort studies (303 participants) for the outcome of abstinence revealed a pooled proportion of 47.5 per cent (95% CI, 42.1\u201352.9; I\n 2<\/jats:sup>\n = 11.7%). The certainty in estimates was very low.\n <\/jats:p>\n <\/jats:sec>\n \n Interpretation & conclusions<\/jats:title>\n The present systematic review and meta-analysis suggest that pharmacological therapies in ALD may reduce overall mortality and the incidence of hepatic decompensation. However, given the very low certainty of evidence, these findings should be interpreted with caution and underscore the need for well-designed trials.<\/jats:p>\n <\/jats:sec>","DOI":"10.25259\/ijmr_2086_2024","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T06:15:43Z","timestamp":1755756943000},"page":"66-73","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacological therapies for alcohol use disorder reduce hepatic decompensation & mortality in alcohol-related liver disease: A GRADE evaluation through a meta-analysis"],"prefix":"10.25259","volume":"162","author":[{"given":"Manya","family":"Prasad","sequence":"first","affiliation":[{"name":"Centre for Community Medicine, All Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Varshney","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Institute of Liver and Biliary Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Maulana Azad Medical College, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"10.25259\/IJMR_2086_2024\/ref-1","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S0140-6736(18)31310-2","article-title":"Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the global burden of disease study 2016","volume":"392","author":"GBD 2016 Alcohol Collaborators","year":"2018","journal-title":"Lancet"},{"key":"10.25259\/IJMR_2086_2024\/ref-2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","article-title":"The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: A systematic analysis for the global burden of disease study 2017","volume":"5","author":"GBD 2017 Cirrhosis collaborators","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.25259\/IJMR_2086_2024\/ref-3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2021.7683","article-title":"Diagnosis and treatment of alcohol-associated liver disease: a review","volume":"326","author":"Singal","year":"2021","journal-title":"JAMA"},{"key":"10.25259\/IJMR_2086_2024\/ref-4","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.jhep.2016.11.011","article-title":"Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease","volume":"66","author":"Lackner","year":"2017","journal-title":"J Hepatol"},{"key":"10.25259\/IJMR_2086_2024\/ref-5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jsat.2015.01.002","article-title":"Examining the Specification validity of the HEDIS quality measures for substance use disorders","volume":"53","author":"Harris","year":"2015","journal-title":"J Subst Abuse Treat"},{"key":"10.25259\/IJMR_2086_2024\/ref-6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.cgh.2010.03.028","article-title":"An explicit quality indicator set for measurement of quality of care in patients with cirrhosis","volume":"8","author":"Kanwal","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.25259\/IJMR_2086_2024\/ref-7","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis","volume":"311","author":"Jonas","year":"2014","journal-title":"JAMA"},{"key":"10.25259\/IJMR_2086_2024\/ref-8","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jama.2018.11406","article-title":"Diagnosis and pharmacotherapy of alcohol use disorder: a review","volume":"320","author":"Kranzler","year":"2018","journal-title":"JAMA"},{"key":"10.25259\/IJMR_2086_2024\/ref-9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.cgh.2015.07.047","article-title":"Efficacy of psychosocial interventions in inducing and maintaining alcohol abstinence in patients with chronic liver disease: A systematic review","volume":"14","author":"Khan","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.25259\/IJMR_2086_2024\/ref-10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-p) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"10.25259\/IJMR_2086_2024\/ref-11","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: A proposal for reporting meta-analysis of observational studies in epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.25259\/IJMR_2086_2024\/ref-14","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: An emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.25259\/IJMR_2086_2024\/ref-15","doi-asserted-by":"publisher","first-page":"e2213014","DOI":"10.1001\/jamanetworkopen.2022.13014","article-title":"Incidence and progression of alcohol-associated liver disease after medical therapy for alcohol use disorder","volume":"5","author":"Vannier","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.25259\/IJMR_2086_2024\/ref-16","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1002\/hep4.2080","article-title":"Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease","volume":"6","author":"Ayyala","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.25259\/IJMR_2086_2024\/ref-17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/alcalc\/agac065","article-title":"Baclofen combined with psychosocial care is useful and safe in alcohol-related cirrhosis patients: A real-life multicenter study","volume":"58","author":"Barrault","year":"2023","journal-title":"Alcohol Alcohol"},{"key":"10.25259\/IJMR_2086_2024\/ref-18","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1097\/MEG.0000000000002304","article-title":"Acamprosate may be safer than baclofen for the treatment of alcohol use disorder in patients with cirrhosis: A first description of use in real-world clinical practice","volume":"34","author":"Tyson","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.25259\/IJMR_2086_2024\/ref-19","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/acer.13944","article-title":"Gender disparities in alcohol use disorder treatment among privately insured patients with alcohol-associated cirrhosis","volume":"43","author":"Mellinger","year":"2019","journal-title":"Alcohol Clin Exp Res"},{"key":"10.25259\/IJMR_2086_2024\/ref-20","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1002\/hep.31042","article-title":"Impact of alcohol use disorder treatment on clinical outcomes among patients with cirrhosis","volume":"71","author":"Rogal","year":"2020","journal-title":"Hepatology"},{"key":"10.25259\/IJMR_2086_2024\/ref-21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.alcohol.2016.12.005","article-title":"A prospective cohort study examining the effectiveness of baclofen in the maintenance of abstinence in alcohol use disorder patients attending a joint liver and alcohol treatment clinic","volume":"62","author":"Owens","year":"2017","journal-title":"Alcohol"},{"key":"10.25259\/IJMR_2086_2024\/ref-22","doi-asserted-by":"publisher","first-page":"e0093","DOI":"10.1097\/HC9.0000000000000093","article-title":"Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis.","volume":"7","author":"Rabiee","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.25259\/IJMR_2086_2024\/ref-23","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1097\/MEG.0000000000000922","article-title":"One year of baclofen in 100 patients with or without cirrhosis: a French real-life experience","volume":"29","author":"Barrault","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.25259\/IJMR_2086_2024\/ref-24","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","article-title":"Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study","volume":"370","author":"Addolorato","year":"2007","journal-title":"Lancet"},{"key":"10.25259\/IJMR_2086_2024\/ref-25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41575-021-00527-0","article-title":"Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation","volume":"19","author":"Arab","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.25259\/IJMR_2086_2024\/ref-26","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3389\/fpsyt.2018.00474","article-title":"Baclofen for the treatment of alcohol use disorder in patients with liver cirrhosis: 10 years after the first evidence","volume":"9","author":"Mosoni","year":"2018","journal-title":"Front Psychiatry"},{"key":"10.25259\/IJMR_2086_2024\/ref-27","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.amjmed.2016.10.004","article-title":"Treatment of alcohol use disorder in patients with alcoholic liver disease","volume":"130","author":"Leggio","year":"2017","journal-title":"Am J Med"},{"key":"10.25259\/IJMR_2086_2024\/ref-28","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1097\/ADM.0000000000001084","article-title":"Simultaneous management of alcohol use disorder and liver disease: A systematic review and meta-analysis","volume":"17","author":"Elfeki","year":"2023","journal-title":"J Addict Med"},{"key":"10.25259\/IJMR_2086_2024\/ref-29","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1002\/hep.31496","article-title":"A Randomized clinical trial of fecal microbiota transplant for alcohol use disorder","volume":"73","author":"Bajaj","year":"2021","journal-title":"Hepatology"},{"key":"10.25259\/IJMR_2086_2024\/ref-30","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.jceh.2022.01.001","article-title":"Long-term outcomes of stool transplant in alcohol-associated hepatitis-analysis of clinical outcomes, relapse, gut microbiota and comparisons with standard care","volume":"12","author":"Philips","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"10.25259\/IJMR_2086_2024\/ref-31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2023.03.003","article-title":"GRADE guidance 36: Updates to GRADE's approach to addressing inconsistency","volume":"158","author":"Guyatt","year":"2023","journal-title":"J Clin Epidemiol"},{"key":"10.25259\/IJMR_2086_2024\/ref-32","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1093\/alcalc\/agu028","article-title":"Utilization of baclofen in maintenance of alcohol abstinence in patients with alcohol dependence and alcoholic hepatitis with or without cirrhosis","volume":"49","author":"Yamini","year":"2014","journal-title":"Alcohol Alcohol"}],"container-title":["The Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ijmr.org.in\/pharmacological-therapies-for-alcohol-use-disorder-reduce-hepatic-decompensation-mortality-in-alcohol-related-liver-disease-a-grade-evaluation-through-a-meta-analysis\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/ijmr.org.in\/pharmacological-therapies-for-alcohol-use-disorder-reduce-hepatic-decompensation-mortality-in-alcohol-related-liver-disease-a-grade-evaluation-through-a-meta-analysis\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T06:13:17Z","timestamp":1758089597000},"score":1,"resource":{"primary":{"URL":"http:\/\/ijmr.org.in\/pharmacological-therapies-for-alcohol-use-disorder-reduce-hepatic-decompensation-mortality-in-alcohol-related-liver-disease-a-grade-evaluation-through-a-meta-analysis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":30,"alternative-id":["10.25259\/IJMR_2086_2024"],"URL":"https:\/\/doi.org\/10.25259\/ijmr_2086_2024","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"article-number":"66"}}